Faraday Pharmaceuticals
Critical Care Medicine

Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. Faraday has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

 


University
Fred Hutchinson Cancer Research Center
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website